Australian Clinical Labs Limited (ASX:ACL)
Australia · Delayed Price · Currency is AUD | Market Cap | 384.10M -32.7% |
| Revenue (ttm) | 737.49M +1.3% |
| Net Income | 26.31M -14.2% |
| EPS | 0.14 -8.2% |
| Shares Out | 186.46M |
| PE Ratio | 14.61 |
| Forward PE | 11.94 |
| Dividend | 0.13 (6.07%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 287,430 |
| Open | 2.070 |
| Previous Close | 2.040 |
| Day's Range | 2.050 - 2.090 |
| 52-Week Range | 1.832 - 2.970 |
| Beta | 0.83 |
| Analysts | Hold |
| Price Target | 2.58 (+25.24%) |
| Earnings Date | Aug 26, 2026 |
About Australian Clinical Labs
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. ... [Read more]
Financial Performance
In fiscal year 2025, Australian Clinical Labs's revenue was 741.27 million, an increase of 6.45% compared to the previous year's 696.37 million. Earnings were 32.43 million, an increase of 35.50%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ACL stock is "Hold." The 12-month stock price target is $2.58, which is an increase of 25.24% from the latest price.
News
Australian Clinical Labs Earnings Call Transcript: H1 2026
Underlying profitability and margins improved despite a 1% revenue decline, driven by operational discipline, digitalization, and portfolio optimization. Guidance anticipates H2 market recovery, with ongoing share buybacks and cost mitigation plans for wage increases.
Australian Clinical Labs Quarterly report: H1 2026
Australian Clinical Labs has published its H1 2026 quarterly earnings report on February 15, 2026.
Australian Clinical Labs Slides: H1 2026
Australian Clinical Labs has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 15, 2026.
Australian Clinical Labs Transcript: AGM 2025
The AGM highlighted strong financial growth, strategic expansion, and operational improvements, with $44 million returned to shareholders. Despite a second strike on the Remuneration Report, all director re-elections were supported, and a new share buyback was announced.
Australian Clinical Labs Slides: FY 2025
Australian Clinical Labs has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 22, 2025.
Australian Clinical Labs Earnings Call Transcript: H2 2025
Revenue grew 6.4% to $741.3M with EBIT up 8.7% and strong cash flow, despite market softness and fee cuts. FY 2026 guidance anticipates continued margin discipline, digital billing, and operational efficiencies, with $8M EBIT uplift expected in FY 2027.
Australian Clinical Labs Annual report: H2 2025
Australian Clinical Labs has published its H2 2025 annual report on August 25, 2025.
Australian Clinical Labs Slides: H2 2025
Australian Clinical Labs has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 25, 2025.
Australian Clinical Labs Earnings release: H2 2025
Australian Clinical Labs released its H2 2025 earnings on August 25, 2025, summarizing the period's financial results.